Regulatory Approval for Targeting the European Schizophrenia Market

The EMA's approval of Rexulti (Rxulti, active ingredient brexpiprazole) signifies that Otsuka Pharmaceutical and Lundbeck have secured a strong growth engine in the European mental health treatment market. This approval follows the 2018 approval for adult schizophrenia and expands the target population to include adolescents aged 13 and older in March 2025, maximizing regulatory completeness. Adolescence is a period when the incidence of schizophrenia rapidly increases, but treatment options have been limited. This expansion of the indication is expected to secure a dominant position in the pediatric and adolescent psychiatry market, which has significant unmet needs. This is a crucial milestone for the two companies to maintain their market share in Europe and build a long-term cash cow, especially as major blockbuster drugs are approaching patent expiration.

Differentiated Pharmacological Mechanism and Clinical Excellence

Rexulti is a Serotonin-Dopamine Activity Modulator (SDAM), and unlike conventional second-generation antipsychotics, it acts as a partial agonist on dopamine D2 and serotonin 5-HT1A receptors. In a pivotal Phase 3 clinical trial in adults, the Rexulti 4mg group showed a statistically significant improvement in the Positive and Negative Syndrome Scale (PANSS) total score compared to placebo (treatment difference -6.47, p=0.0022). In addition, a 6-week Phase 3 trial involving 316 adolescent schizophrenia patients demonstrated excellent tolerability and symptom improvement, objectively confirming the safety of the drug in pediatric and adolescent patients. These comprehensive clinical data maximize the drug's reliability and will serve as strong clinical evidence for conservative European physicians to prescribe the drug.

Global Revenue Growth and the Value of Partnerships

Rexulti is a key pipeline product developed under the 2011 joint development agreement between Otsuka Pharmaceutical and Lundbeck, and it is a core pillar supporting the financial growth of both companies. In 2024, Lundbeck recorded 5.2 billion DKK (Danish kroner, approximately USD 750 million) in revenue from Rexulti, and Otsuka Pharmaceutical reported strong global revenue of 267.4 billion JPY (Japanese yen, approximately USD 1.8 billion). The two companies adopted a strategy of sharing the initial risks of joint development and conducting co-promotion by leveraging their respective regional strengths. This collaborative model is expected to maximize synergy in local distribution and hospital bidding processes after approval, leading to rapid revenue growth across Europe.

Changes and Prospects in Schizophrenia Treatment Paradigms

The global schizophrenia treatment market is rapidly shifting towards minimizing side effects and improving patient compliance. Rexulti effectively suppresses excessive dopamine stimulation while significantly reducing the incidence of common side effects associated with existing drugs, such as akathisia and weight gain. This safety profile is a key differentiator that reduces the rate of discontinuation and recurrence in schizophrenia patients, who require long-term medication. Ultimately, beyond regulatory approval, it is expected to create a positive virtuous cycle by increasing the rate of social reintegration for patients and reducing long-term healthcare costs.